Cargando…
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cells, exemplified by bispecific T cell engagers (...
Autores principales: | Tian, Zheng, Liu, Ming, Zhang, Ya, Wang, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091790/ https://www.ncbi.nlm.nih.gov/pubmed/33941237 http://dx.doi.org/10.1186/s13045-021-01084-4 |
Ejemplares similares
-
Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019) -
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
por: Omer, Mohamed H., et al.
Publicado: (2023) -
The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021) -
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
por: Viardot, Andreas, et al.
Publicado: (2020) -
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
por: Heidbuechel, Johannes P. W., et al.
Publicado: (2021)